Berkeley Lights, Inc.
5858 Horton Street, Suite 320
Emeryville
CA
94608
United States
Website: http://www.berkeleylights.com/
11 articles about Berkeley Lights, Inc.
-
Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020
10/19/2020
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be report financial results for the third quarter 2020 after market close on Thursday, November 12, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the Company’s website at:
-
Berkeley Lights, Inc. And Amyris Announce Collaboration To Speed Testing Of Microbial Strains
6/10/2019
Berkeley Lights, Inc., the leader in digital cell biology, and Amyris, Inc., a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets, announced that they have entered into a collaboration focused on improving the production of high-value, small molecule, natural products from Amyris' microbial strains.
-
Harbour BioMed Integrates the Beacon® Platform to Accelerate Antibody Discovery
1/22/2019
Berkeley Lights Further Extends into Asian Market
-
Berkeley Lights Announces Collaboration with University of Pennsylvania to Advance CAR-T Therapeutics
1/3/2019
Berkeley Lights, Inc. announced today that it has entered into a collaboration to explore multiple lines of inquiry aimed at advancing cellular therapies, including CAR-T therapeutics, with Megan Suhoski Davis, Director of the Product Development Laboratory (PDL) within the Center for Cellular Immunotherapies in the University of Pennsylvania's Perelman School of Medicine (Penn Medicine).
-
Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform
10/18/2018
Effort Designed to Safely and Efficiently Speed Drug Candidates into the Clinic
-
Berkeley Lights Closes $95 Million Funding Round To Expedite Commercial Expansion And Platform Development For Cell Therapy
10/15/2018
Financing will also be used to drive R&D and further expand commercial activities for digital cell biology worldwide
-
Berkeley Lights and TPG Biologics Enter into a Strategic Collaboration for Cell Line Development
5/23/2018
Program Implements Beacon Platform for Creating Workflow Efficiencies to Accelerate the Drug Development Process
-
Berkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
4/19/2018
Berkeley Lights, Inc. (BLI) announced today Sanofi purchased the Beacon platform to accelerate their cell line development (CLD) process.
-
MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer
3/7/2018
Optera Therapeutics will develop cancer cell therapies discovered at MD Anderson and apply Berkeley Lights' advanced cell therapy manufacturing systems with the goal of making these novel therapies accessible to all.
-
Berkeley Lights Forms Strategic Scientific Advisory Board Featuring Distinguished Experts
12/4/2017
The SSAB serves as a strategic resource for Berkeley Lights as it continues to build out its product portfolio in the areas of drug discovery and development, and cell therapy manufacturing.
-
Teva Pharmaceuticals Australia, Pty. Ltd. Implements Berkeley Lights' Beacon OptoFluidic Platform for Antibody Discovery
11/29/2017
Berkeley Lights announced today that Teva Pharmaceuticals Australia, Pty. Ltd. has implemented BLI's Beacon platform in their antibody discovery programs.